The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death
Cancer immunotherapy is a strategy that is moving to the frontier of cancer treatment in the current decade. In this study, we show evidence that 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs), act as immunogenic cell death (ICD) inducers, stimulating an antitumor response...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2021-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_833feb7b030d426a96d2efbd4c05e78f | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Xiao-Chuan Duan |e author |
| 700 | 1 | 0 | |a Li-Yuan Peng |e author |
| 700 | 1 | 0 | |a Xin Yao |e author |
| 700 | 1 | 0 | |a Mei-Qi Xu |e author |
| 700 | 1 | 0 | |a Hui Li |e author |
| 700 | 1 | 0 | |a Shuai-Qiang Zhang |e author |
| 700 | 1 | 0 | |a Zhuo-Yue Li |e author |
| 700 | 1 | 0 | |a Jing-Ru Wang |e author |
| 700 | 1 | 0 | |a Zhen-Han Feng |e author |
| 700 | 1 | 0 | |a Guang-Xue Wang |e author |
| 700 | 1 | 0 | |a Ai Liao |e author |
| 700 | 1 | 0 | |a Ying Chen |e author |
| 700 | 1 | 0 | |a Xuan Zhang |e author |
| 245 | 0 | 0 | |a The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death |
| 260 | |b Taylor & Francis Group, |c 2021-01-01T00:00:00Z. | ||
| 500 | |a 1071-7544 | ||
| 500 | |a 1521-0464 | ||
| 500 | |a 10.1080/10717544.2021.1909180 | ||
| 520 | |a Cancer immunotherapy is a strategy that is moving to the frontier of cancer treatment in the current decade. In this study, we show evidence that 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs), act as immunogenic cell death (ICD) inducers, stimulating an antitumor response which results in synergistic antitumor activity by combining anti-PD-L1 antibody (aPD-L1) in vivo. To investigate the antitumor immunity induced by NPPA-PTX NPs, the expression of both ICD marker calreticulin (CRT) and high mobility group box 1 (HMGB1) were analyzed. In addition, the antitumor activity of NPPA-PTX NPs combined with aPD-L1 in vivo was also investigated. The immune response was also measured through quantitation of the infiltration of T cells and the secretion of pro-inflammatory cytokines. The results demonstrate that NPPA-PTX NPs induce ICD of MDA-MB-231 and 4T1 cells through upregulation of CRT and HMGB1, reactivating the antitumor immunity via recruitment of infiltrating CD3+, CD4+, CD8+ T cells, secreting IFN-γ, TNF-α, and the enhanced antitumor activity by combining with aPD-L1. These data suggest that the combined therapy has a synergistic antitumor activity and has the potential to be developed into a novel therapeutic regimen for cancer patients. | ||
| 546 | |a EN | ||
| 690 | |a 3-(2-nitrophenyl) propionic acid-paclitaxel | ||
| 690 | |a nanoparticles | ||
| 690 | |a immunogenic cell death | ||
| 690 | |a anti-pd-l1 antibody | ||
| 690 | |a immune response | ||
| 690 | |a synergistic antitumor activity | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Drug Delivery, Vol 28, Iss 1, Pp 800-813 (2021) | |
| 787 | 0 | |n http://dx.doi.org/10.1080/10717544.2021.1909180 | |
| 787 | 0 | |n https://doaj.org/toc/1071-7544 | |
| 787 | 0 | |n https://doaj.org/toc/1521-0464 | |
| 856 | 4 | 1 | |u https://doaj.org/article/833feb7b030d426a96d2efbd4c05e78f |z Connect to this object online. |